8-K: Sensus Healthcare Q3 2026 Revenue Declines, Gross Margin Improves

Sensus Healthcare reported a 13.0% decrease in third-quarter 2026 revenue to $6.0 million, though gross profit rose to $3.3 million with a 55% margin, and system shipments increased.

Summary

• Sensus Healthcare announced its financial results for the third quarter of 2026.
• Revenues decreased by 13.0% to $6.0 million compared to $6.9 million in Q3 2025.
• This decline was attributed to a product mix shift towards lower-priced SRT-100 systems and the absence of sales to a historically large customer.
• Gross profit increased by 22.2% to $3.3 million, with gross margin improving to 55% from 39.1% in the prior year.
• The company shipped 26 systems, an increase from 16 systems in Q3 2025, with 8 systems carried over from Q2 2026.
• Net loss widened to $1.5 million ($0.09 per share) from $0.9 million ($0.06 per share) in Q3 2025.
• Adjusted EBITDA improved to a negative $1.5 million from a negative $2.4 million in the prior year.
• Cash, restricted cash, and cash equivalents stood at $12.9 million as of September 30, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed to slightly negative quarter due to declining revenues and an increased net loss, despite improvements in gross margin and system shipments.

Positives

• Gross profit increased to $3.3 million from $2.7 million in Q3 2025.
• Gross margin improved significantly to 55% from 39.1% in the prior-year period.
• System shipments increased to 26 units from 16 units year-over-year.
• Adjusted EBITDA showed improvement, moving from negative $2.4 million to negative $1.5 million.
• The company placed its 1,000th SRT system subsequent to the quarter end, a significant commercial milestone.
• Continued physician education initiatives and expanded customer relationships, including initial purchases by two large private equity-backed dermatology groups.
• Launched TreatSkinCancer.com, a consumer education resource.
• Advanced international market-development activities.

Negatives

• Revenue decreased by 13.0% to $6.0 million compared to $6.9 million in Q3 2025.
• Net loss increased to $1.5 million ($0.09 per share) from $0.9 million ($0.06 per share) in Q3 2025.
• The absence of sales to a historically large customer impacted revenue.
• Cash, restricted cash, and cash equivalents decreased to $12.9 million from $15.2 million at the end of Q2 2026.

Risks

• The level and availability of government and/or third-party payor reimbursement for clinical procedures using their products, and the willingness of healthcare providers to purchase products if reimbursement declines.
• Concentration of customers in the U.S.
• Development by competitors of new products, treatments, or technologies that could render Sensus Healthcare's technology obsolete.
• Regulatory requirements applicable to the company and its competitors.
• Ability to efficiently manage manufacturing processes and costs.
• Risks arising from doing business in China and other foreign countries, including geopolitical tensions.
• Legislation, regulation, or other governmental action affecting products, taxes, international trade regulation (including tariffs).
• Performance of information technology systems and ability to maintain data security.

Future Outlook

Management commentary suggests a focus on converting opportunities into sales, increasing system utilization, and building a more diversified, sustainably profitable business, supported by dedicated reimbursement codes and expanded physician education and patient awareness initiatives.

Management Comments

• "Our third quarter results reflect continued progress in building a broader, more diversified customer base and advancing our business toward sustainable profitability."
• "With dedicated reimbursement codes now in effect, our conversations with physicians are increasingly focused on how to bring SRT into their practices."
• "Our vision is to make SRT a more widely understood and accessible non-invasive treatment option for appropriate patients with non-melanoma skin cancer."
• "We are expanding physician education and patient awareness, including through TreatSkinCancer.com, while pursuing opportunities internationally and developing additional revenue streams tied to system utilization, software and services."
• "The recent sale of our 1,000th SRT system is a milestone I am particularly proud of."
• "We have spent years advancing the technology and growing our installed base. Today, we have a reimbursement framework that we believe can support broader adoption and a more scalable business."
• "Our focus is on converting these opportunities into sales, increasing utilization and building a more diversified, sustainably profitable business."

Industry Context

StockSavvy.ai notes that Sensus Healthcare operates in the medical device sector, specifically focusing on non-invasive treatments for skin conditions. The company's strategy appears to be shifting towards broader physician engagement and customer diversification, which is a common trend in the medtech industry as companies seek to reduce reliance on single large customers and build more stable revenue streams. The emphasis on reimbursement codes and patient awareness is critical for adoption of new medical technologies.

Stakeholder Impact

• Shareholders: The increased net loss and declining revenue may negatively impact shareholder value in the short term, although improved gross margins and increased shipments offer some positive indicators for future performance.
• Customers: The company's focus on broader physician engagement and customer diversification aims to provide more stable access to their treatment technology.
• Employees: Potential impacts from R&D expense reduction and headcount changes mentioned in the filing.
• Suppliers: Not directly addressed, but changes in product mix and sales volume could influence demand for components.

Next Steps

• Continue physician education initiatives.
• Expand customer relationships and support customer expansion.
• Increase patient awareness of skin cancer treatment options.
• Pursue international market-development activities.
• Develop additional revenue streams tied to system utilization, software, and services.
• Focus on converting opportunities into sales and increasing system utilization.
• Build a more diversified, sustainably profitable business.

Key Dates

Recommendation

The company shows positive operational improvements in gross margin and unit shipments, and management is focused on strategic growth initiatives. However, the decline in revenue and widening net loss are significant concerns. A 'hold' recommendation reflects a balanced view, awaiting further evidence of revenue recovery and sustained profitability before considering a more positive outlook.

Keywords

Sensus Healthcare, SRT-100, dermatology, skin cancer treatment, medical device, radiotherapy, financial results, Q3 2026